{"id":46989,"date":"2022-08-05T16:02:13","date_gmt":"2022-08-05T14:02:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bispecific-molecules-oncology-analytical-tool-2022-coverage-of-170-companies-plus-partners-developing-484-bispecific-drugs-where-411-are-in-active-development-across-177-different-targets-researcha\/"},"modified":"2022-08-05T16:02:13","modified_gmt":"2022-08-05T14:02:13","slug":"bispecific-molecules-oncology-analytical-tool-2022-coverage-of-170-companies-plus-partners-developing-484-bispecific-drugs-where-411-are-in-active-development-across-177-different-targets-researcha","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bispecific-molecules-oncology-analytical-tool-2022-coverage-of-170-companies-plus-partners-developing-484-bispecific-drugs-where-411-are-in-active-development-across-177-different-targets-researcha\/","title":{"rendered":"Bispecific Molecules Oncology Analytical Tool 2022: Coverage of 170 Companies Plus Partners Developing 484 Bispecific Drugs Where 411 are in Active Development Across 177 Different Targets – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Bispecific Molecules in Oncology: Analytical Tool”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nBispecific Molecules in Oncology: Analytical Tool is the must have handbook for any business developer, BI\/CI operative or clinical developer who needs to be on top of this hot and fast moving area of oncology.\n<\/p>\n

\nThis unique product is truly the only tool of its kind and is designed to give you a competitive edge in your bispecific drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.\n<\/p>\n

\nYour Bispecific Molecules in Oncology: Analytical Tool covers more than 170 companies plus partners who are today developing 484 bispecific drugs where of 411 are in active development in cancer across 177 different targets. Any data and\/or analysis from the Analytical Tool is yours to keep and data\/graphs\/tables can be easily exported into Excel\/PDF and various graphic formats for mixing with your own proprietary information.\n<\/p>\n

\nFor 20 years we have supported better decision making across the oncology drug development industry. Your Bispecific Molecules in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer’s desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.\n<\/p>\n

\nLet our expertise work for you<\/strong>\n<\/p>\n

\nWith a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.\n<\/p>\n

\nYour key to access development at the world-leading cancer meetings<\/strong>\n<\/p>\n

\nThe Bispecific Molecules in Oncology: Analytical Tool is continuously updated according to twelve of the world’s most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.\n<\/p>\n

\nRun combination therapy analysis like no other<\/strong>\n<\/p>\n

\nThe Bispecific Molecules in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.\n<\/p>\n

\nUnparalleled biomarker surveillance<\/strong>\n<\/p>\n

\nWe also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.\n<\/p>\n

\nSupport and inspiration at your finger-tips<\/strong>\n<\/p>\n

\nYou also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.\n<\/p>\n

\nA tool to grow with and keep you informed<\/strong>\n<\/p>\n

\nUnlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.\n<\/p>\n

\nBispecific Molecules in Oncology: Analytical Tool achieves this by continuously scanning development in bispecific and reporting:<\/strong>\n<\/p>\n